Biotech Acquisition Company (NASDAQ:NAAC) announced this morning that it has for a second time postponed its special meeting to approve its combination with Blade Therapeutics.
This meeting was first pushed back from June 1 and the SPAC has not yet set a new date. As with the previous postponement, Biotech noted that it has obtained sufficient votes to approve the transaction but it needs additional time to satisfy all closing conditions. The record date for the vote remains unchanged as March 28.
Biotech is required to maintain at least $75 million in cash available through its trust and PIPE proceeds in order for the deal to close. It initially announced a $24.3 million PIPE and signed a common stock purchase agreement on May 9 with an affiliate of Cantor Fitzgerald for it to purchase up to $75 million in the combined company’s shares post-close.
Biotech, which raised $230 million at IPO, initially announced its $352.8 million deal with Blade Therapeutics on November 8. San Francisco-based Blade Therapeutics is developing three drug candidates as potential therapies against varying forms of organ fibrosis with its most advanced having completed Phase I.
In April, Blade announced that the FDA has provided the feedback necessary in order for it to proceed to Phase II proof of concept and dose-ranging studies for its cudetaxestat drug candidate.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...